



■ TEL. : 022 - 6825 2525  
■ FAX : 022 - 2405 7708  
■ E-Mail : info@naxparlab.com  
■ Visit us at: www.naxparlab.com  
■ CIN No. : L36912MH1982PLC027925

# Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,  
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 14/08/2021

To,  
Department of Corporate Service (DCS-CRD),  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400001.

**Sub: Submission of Un-Audited Standalone and Consolidated Financial Results for quarter ended 30<sup>th</sup> June, 2021 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.**

**Ref: Parnax Lab Limited, Script Code- 506128**

Dear Sir,

Kindly find enclosed herewith the following:

1. A Copy of Standalone & Consolidated Un-Audited Financial results with Limited Review Report of the Company for the quarter ended 30th June 2021;

Kindly take on your record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For PARNAX LAB LIMITED



PREET KUKREJA  
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl: As above

To  
**The Board of Directors,**  
**Parnax Lab Limited,**  
114, Building No. 8,  
Jogani Industrial Complex,  
Chunabhatti, Mumbai – 400 022

1. We have reviewed the unaudited standalone financial results of **Parnax Lab Limited** ("the company") for the quarter and three months ended June 30, 2021 which are included in the accompanying "Statement of Unaudited Standalone Financial Result for the quarter and three months ended June 30, 2021" together with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Ladha Singhal and Associates**  
Chartered Accountants  
(FRN: 120241W)

*Vinod Ladha*

(Vinod Ladha)

Partner

M. No. : 104151

Place : Mumbai

Dated : 14<sup>th</sup> August, 2021

UDIN : 21104151AAAAFP6466



**PARNAX LAB LIMITED**

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.  
Tel : 022 - 68252525, Fax : 2405 7708, Email : compliance@parnaxlab.com, Website : www.parnaxlab.com  
CIN:-L36912MH1982PLC027925

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2021**

S. No.	Particulars	(Rs. in Lakhs)			
		Quarter Ended		Year Ended	
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
I	Revenue from Operations	174.33	77.29	21.74	237.28
II	Other Income	2.75	0.57	0.73	6.51
III	<b>Total Revenue (I+II)</b>	<b>177.08</b>	<b>77.86</b>	<b>22.47</b>	<b>243.79</b>
IV	Expenses				
	a) Cost of Material Consumed	38.00	8.14	0.08	28.39
	b) Purchase of Stock in trade	55.24	42.55	15.57	117.42
	c) Changes in inventories of finished goods, Work in progress and stock in trade	-	-	-	-
	d) Employer benefits expenses	9.38	8.98	10.91	44.72
	e) Finance Costs	18.12	18.00	21.72	83.00
	f) Depreciation and amortisation expenses	1.02	1.08	1.10	4.40
	g) Other expenses	26.78	38.65	10.31	91.22
	<b>Total Expenses (IV)</b>	<b>148.54</b>	<b>117.40</b>	<b>59.69</b>	<b>369.15</b>
V	Profit/(Loss) before exceptional items and tax (III-IV)	28.54	(39.54)	(37.22)	(125.36)
VI	Exceptional Items	-	-	-	-
VII	<b>Profit/(Loss) Before Tax (V-VI)</b>	<b>28.54</b>	<b>(39.54)</b>	<b>(37.22)</b>	<b>(125.36)</b>
VIII	Tax expense	-	(12.31)	-	(12.31)
IX	<b>Profit/(Loss) for the period (VII-VIII)</b>	<b>28.54</b>	<b>(27.23)</b>	<b>(37.22)</b>	<b>(113.05)</b>
X	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	3.06	-	3.06
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.77)	-	(0.77)
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	<b>Total Other Comprehensive Income for the period</b>	<b>-</b>	<b>2.29</b>	<b>-</b>	<b>2.29</b>
XII	<b>Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)</b>	<b>28.54</b>	<b>(24.94)</b>	<b>(37.22)</b>	<b>(110.76)</b>
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49
XIV	Earning per equity share (Not Annualised)				
	(1) Basic	0.34	(0.32)	(0.44)	(1.33)
	(2) Diluted	0.34	(0.32)	(0.44)	(1.33)

**Notes-**

- The Financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2021.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2021
- EPS for quarter ended is on non annualized basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- There is no material adverse impact of First / Second wave of COVID-19 pandemic on the Company and its subsidiary company operations / profitability during the quarter ended June 30, 2021 and period thereafter
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board  
For Parnax Lab Limited



Prakash M Shah  
Director & CEO  
DIN NO: 00440980


Place : Mumbai  
Date : 14-08-2021



To  
**The Board of Directors,**  
**Parnax Lab Limited,**  
114, Building No. 8, Jogani Industrial Complex,  
Chunabhatti, Mumbai - 400 022

1. We have reviewed the unaudited Consolidated financial results of **Parnax Lab Limited** ("the company") and **Naxpar Pharma Private Limited** ("the Subsidiary") for the quarter and three months ended June 30, 2021 which are included in the accompanying "Statement of Unaudited Consolidated Financial Result for the quarter and three months ended June 30, 2021" together with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than as audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Ladha Singhal and Associates**  
Chartered Accountants  
(FRN: 120241W)

  
(Vinod Ladha)


Partner

M. No. : 104151

Place : Mumbai

Dated : 14<sup>th</sup> August, 2021

UDIN : 21104157 AAAA FC 7941




**PARNAX LAB LIMITED**  
 GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABIATTI, MUMBAI 400022,  
 Tel : 022 - 68252525, Fax : 2405 7708, Email : compliance@naxparlab.com, Website : www.naxparlab.com  
 CIN:-L36912MH1982PLC027925  
**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2021**

S. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
I	Revenue from Operations	2,869.43	2,048.17	1,746.16	8,951.98
II	Other Income	3.53	9.14	2.66	21.03
III	<b>Total Revenue (I+II)</b>	<b>2,872.96</b>	<b>2,057.31</b>	<b>1,748.82</b>	<b>8,973.01</b>
IV	Expenses				
	a) Cost of Material Consumed	1,555.58	984.87	824.24	4,040.83
	b) Purchase of Stock in trade	58.12	5.71	47.64	36.28
	c) Changes in inventories of finished goods, Work in progress and stock in trade	(133.88)	(5.55)	(32.06)	44.75
	d) Employee benefits expenses	377.70	380.72	269.99	1,368.35
	e) Finance Cost	117.22	126.83	124.96	508.11
	f) Depreciation and amortisation expenses	125.52	133.10	122.80	515.97
	g) Other expenses	675.11	714.47	368.02	2,467.10
	<b>Total Expenses (IV)</b>	<b>2,775.37</b>	<b>2,340.15</b>	<b>1,725.59</b>	<b>8,981.39</b>
V	Profit/(loss) before exceptional items and tax (III-IV)	97.59	(282.84)	23.23	(8.35)
VI	Exceptional Items	-	-	-	-
VII	<b>Profit/(loss) Before Tax (V+VI)</b>	<b>97.59</b>	<b>(282.84)</b>	<b>23.23</b>	<b>(8.35)</b>
VIII	Tax expense	-	27.69	-	27.69
IX	<b>Profit/(Loss) After Tax for the period (VII-VIII)</b>	<b>97.59</b>	<b>(310.53)</b>	<b>23.23</b>	<b>(36.07)</b>
X	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	15.21	-	15.21
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(3.93)	-	(3.93)
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	<b>Total Other Comprehensive Income for the period</b>	<b>-</b>	<b>11.28</b>	<b>-</b>	<b>11.28</b>
XII	<b>Total Comprehensive Income comprising profit and other comprehensive income for the period (IX + XIII)</b>	<b>97.59</b>	<b>(299.25)</b>	<b>23.23</b>	<b>(24.79)</b>
XIII	<b>Total profit/(loss) for the year attributable to:</b>				
	- Owners of the Company	97.45	(309.96)	23.11	(36.22)
	- Non-controlling interests	0.14	(0.57)	0.12	0.15
XIV	<b>Other Comprehensive Income attributable to:</b>				
	- Owners of the Company	-	11.26	-	11.26
	- Non-controlling interests	-	0.02	-	0.02
XV	<b>Total Comprehensive Income attributable to:</b>				
	- Owners of the Company	97.45	(298.70)	23.11	(24.96)
	- Non-controlling interests	0.14	(0.55)	0.12	0.17
XVI	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49
XVII	Earnings per equity share (Not Annualised)				
	(1) Basic	1.15	(3.65)	0.27	(0.42)
	(2) Diluted	1.15	(3.65)	0.27	(0.42)

**Notes-**

- The Financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2021
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2021
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- There is no material adverse impact of First / Second wave of COVID-19 pandemic on the Company and its subsidiary company operations / profitability during the quarter ended June 30, 2021 and period thereafter
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai  
 Date : 14-08-2021

By Order of the Board  
 For Parnax Lab Limited  
  
 Prakash M Shah  
 Whole Time Director & CEO  
 DIN NO: 00440980

